Hyderabad biotech agency, Japanese entity ink pact

UR Advanced Therapeutics (URAT), the Hyderabad-based biotechnology agency behind BioVaram model, and Japanese firm Teijin have signed an settlement to leverage every firm’s strengths to ship options throughout each nations.

Specifically, the settlement is to discover alternatives for increasing utilization of Teijin Group’s implantable medical units and regenerative drugs merchandise in India in addition to introducing BioVaram’s product portfolio into the Japanese market.

Teijin and URAT will discover regulatory approval and commercialisation of Teijin Medical Technologies cardiovascular restore patch Synfolium in India; and alternatives for increasing use of Japan Tissue Engineering Co’s regenerative drugs merchandise in India. They will work for improvement and commercialisation of BioVaram applied sciences in Japan, together with exosome-based diagnostics and therapeutics, Extracellular Matrix mimics, and bio-derived supplies corresponding to Type I atelocollagen.

“By combining the experience of each corporations, we’re assured in our skill to ship revolutionary therapies that deal with unmet medical wants in each nations,” stated Takayuki Nakano, mission government and normal manager-Regenerative Medicine and Implantable Medical Device Division of Teijin.

URAT founder and CEO Jaganmohan Reddy stated the “partnership strengthens our capabilities in analysis, innovation and scalable manufacturing of superior tissue engineering merchandise, whereas enabling Teijin to take BioVaram’s merchandise to world markets.”

The two corporations will assess enterprise feasibility, regulatory pathways, technical integration and market must advance these initiatives. They will even collaborate on product improvement and manufacturing in cell and gene remedy and pursue plans for introducing Synfolium in India, the businesses stated in a launch on Thursday (November 13, 2025).